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David A LoefflerErratum
After publication of our article [1], it came to our
attention that we had erroneously stated that the IVIG
product NewGam was produced by Sutter Health.
However, Octapharma is the manufacturer of NewGamTM
and Sutter Health is the sponsor of the clinical trial.
Therefore the following sentence on page 2 of the original
manuscript [1] is incorrect: "The effects of Sutter Health's
IVIG NewGamTM are also being examined in individuals
with mild cognitive impairment (MCI) [33], thought to be
the transitional state between the cognitive changes of
normal aging and very early dementia [34]." This sentence
should read as follows: “The effects of Octapharma's IVIG
NewGamTM are also being examined in individuals with
mild cognitive impairment (MCI) [33], thought to be the
transitional state between the cognitive changes of normal
aging and very early dementia [34].”
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